Nosology

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

Retrieved on: 
월요일, 3월 16, 2020
Medical diagnosis, Medical terminology, Nosology, Meridian Bioscience

Many Molecular Diagnostic companies in the United States, China, and Europe have already incorporated Meridians technologies in their assays.

Key Points: 
  • Many Molecular Diagnostic companies in the United States, China, and Europe have already incorporated Meridians technologies in their assays.
  • Meridian is committed to supplying solutions to the diagnostic industry during times of a pandemic health crisis.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.
  • Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing.

Rapid Diagnostic Test for Coronavirus COVID-19 Now Available from Surgisphere

Retrieved on: 
목요일, 3월 12, 2020
General Health, Infectious diseases, Health, Data management, Technology, Health, Viruses, Medicine, Medical diagnosis, Medical terminology, Nosology, Middle East respiratory syndrome-related coronavirus

Surgisphere Corporation announces the availability of a rapid diagnostic tool for novel coronavirus.

Key Points: 
  • Surgisphere Corporation announces the availability of a rapid diagnostic tool for novel coronavirus.
  • Early diagnosis means faster treatment, which means more lives saved, stated Dr. Sapan Desai, President and Chief Executive Officer of Surgisphere.
  • Surgisphere used its cloud-based healthcare data analytics platform (QuartzClinical) to identify patients diagnosed with COVID-19 in five countries.
  • Surgisphere is seeking physicians and healthcare systems to work collaboratively by sharing data to increase the sample size of COVID-19 patients.

Prognos Health Announces Launch of Rare Disease Institute

Retrieved on: 
금요일, 2월 28, 2020
Medical terminology, Medical diagnosis, Nosology

NEW YORK, Feb. 28, 2020 /PRNewswire/ --Prognos Health, an AI-driven platform company focused on predicting the trajectory of disease to drive informed decisions earlier in the patient journey, today announced the launch of the Rare Disease Institute (RDI), a collaborative initiative among critical healthcare stakeholders focused on improving testing, diagnosis and treatment of rare disease.

Key Points: 
  • NEW YORK, Feb. 28, 2020 /PRNewswire/ --Prognos Health, an AI-driven platform company focused on predicting the trajectory of disease to drive informed decisions earlier in the patient journey, today announced the launch of the Rare Disease Institute (RDI), a collaborative initiative among critical healthcare stakeholders focused on improving testing, diagnosis and treatment of rare disease.
  • "We believe including the patient perspective and voice in rare disease research is imperative," said Keely Haag, Director of Operations, United Leukodystrophy Foundation.
  • The RDI's aim is to orchestrate the sequence that will best serve the patient suffering from a rare disease.
  • Prognos Health is an AI platform company focused on predicting thetrajectory of disease to drive decisions earlier in healthcare in collaboration with payers, life sciences and providers.

Short-Term Health Plans Leave Patients Vulnerable to Major Medical Bills, According to New Research from The Leukemia & Lymphoma Society

Retrieved on: 
화요일, 2월 25, 2020
Medical terminology, Medical diagnosis, Nosology, Caregiver

"The findings of this study confirm what we long suspected that the design of these plans leaves patients vulnerable to expensive bills," said Gwen Nichols, MD, LLS chief medical officer.

Key Points: 
  • "The findings of this study confirm what we long suspected that the design of these plans leaves patients vulnerable to expensive bills," said Gwen Nichols, MD, LLS chief medical officer.
  • "Short-term plans don't offer typical health insurance benefits and provide very little protection when a patient faces a serious, unexpected diagnosis.
  • LLS is working at the state and federal levels to protect patients from these dangerous plans.
  • We urge cancer patients and their caregivers to ask questions about whether their treatments are covered by these plans, given their serious shortfalls."

Cue Health Inc, Product Pipeline Analysis, 2019 Update - Analysis, Key Developments & Key Competitors - ResearchAndMarkets.com

Retrieved on: 
금요일, 1월 24, 2020
Biotechnology, Health, Clinical trials, Health, Articles, Medical diagnosis, Medical terminology, Nosology, Health care, Cue

The "Cue Health Inc - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cue Health Inc - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.
  • Cue Health Inc (Cue Health) operates as a healthcare technology company that strives to design, develop, manufacture and commercialize medical diagnostic products for use in home and clinical settings.
  • The company's lead product, Cue Health Monitoring System, is a connected diagnostic platform that helps in testing clinical samples in a disposable test cartridge and delivering results to a mobile device.
  • Its product finds application in the detection, diagnosis and management of women's health, infectious diseases, cardiovascular health, wellness, and other diseases.

Patient Power® Fuels Patient Action with Reporting on Blood Cancer Progress Seen at the American Society of Hematology Annual Meeting

Retrieved on: 
월요일, 12월 23, 2019
Medicine, Medical terminology, Health, Articles, Medical diagnosis, Nosology, Health informatics, Telehealth

Patient Power is a patient-centric, mission-driven media organization dedicated to providing actionable information and support to people affected by cancer.

Key Points: 
  • Patient Power is a patient-centric, mission-driven media organization dedicated to providing actionable information and support to people affected by cancer.
  • Through its multiple programs, Patient Power empowers patients and their care partners with the most up-to-date and salient information to make savvy treatment decisions.
  • Patient Power also amplifies the voice of people it reaches, delivering their insights to interested parties, including the media, government and companies that develop medical products.
  • Patient Power's mission is to help patients and care partners, from diagnosis on, approach cancer in way that accelerates their journey to the best possible health.

Bipartisan Legislation Increasing Research Funding to Improve Diagnosis Introduced in U.S. House Following SIDM Research Release

Retrieved on: 
금요일, 11월 22, 2019
Medical terminology, Medical diagnosis, Nosology, Medicine, Diagnosis, Gus Bilirakis, Draft:Society to Improve Diagnosis in Medicine

Bipartisan legislation, Improving Diagnosis in Medicine Act of 2019, was introduced by U.S. House Assistant Speaker Ben Ray Lujn (D-NM) and Rep. Gus Bilirakis (R-FL) on November 13.

Key Points: 
  • Bipartisan legislation, Improving Diagnosis in Medicine Act of 2019, was introduced by U.S. House Assistant Speaker Ben Ray Lujn (D-NM) and Rep. Gus Bilirakis (R-FL) on November 13.
  • Finally, it adds diagnosis as new category to the federal database that formally tracks health research funding.
  • The Society to Improve Diagnosis in Medicine catalyzes and leads change to improve diagnosis and eliminate harm from diagnostic error.
  • In 2015, SIDM established the Coalition to Improve Diagnosis to increase awareness and actions that improve diagnosis.

Society to Improve Diagnosis in Medicine Announces President-Elect and New Board Member

Retrieved on: 
월요일, 11월 11, 2019
Medical terminology, Medical diagnosis, Nosology, Medicine, Diagnosis

Dr. Trowbridge is an Associate Professor of Medicine at Tufts University School of Medicine and Director of Undergraduate Medical Curriculum at Maine Medical Center in Portland, Maine.

Key Points: 
  • Dr. Trowbridge is an Associate Professor of Medicine at Tufts University School of Medicine and Director of Undergraduate Medical Curriculum at Maine Medical Center in Portland, Maine.
  • "The Society to Improve Diagnosis in Medicine continues to make major strides towards improving diagnostic quality and safety in our healthcare system.
  • The Society to Improve Diagnosis in Medicine catalyzes and leads change to improve diagnosis and eliminate harm from diagnostic error.
  • In 2015, SIDM established the Coalition to Improve Diagnosis to increase awareness and actions that improve diagnosis.

Hillrom to Present at the Stifel 2019 Healthcare Conference

Retrieved on: 
화요일, 10월 29, 2019
Medical diagnosis, Medical terminology, Nosology

CHICAGO, Oct. 29, 2019 /PRNewswire/ --Hillrom (NYSE: HRC) today announced that it will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019, in New York.

Key Points: 
  • CHICAGO, Oct. 29, 2019 /PRNewswire/ --Hillrom (NYSE: HRC) today announced that it will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019, in New York.
  • John Groetelaars, Hillrom's president and chief executive officer, is scheduled to present at 2:25 p.m. Eastern Time.
  • Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by advancing connected care.
  • They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting carecloser to home.

PredictImmune Announces a Strategic Agreement With Theradiag for French Speaking Europe to Commercialise PredictSURE IBD™, the World’s First Validated Prognostic Test for Inflammatory Bowel Disease

Retrieved on: 
월요일, 10월 28, 2019
Biotechnology, Pharmaceutical, Health, Medical devices, Medical terminology, Medicine, Health, Medical diagnosis, Nosology, Prognosis, Autoimmune diseases

This latest partnership follows the successful launch of PredictSURE IBD in the UK and Ireland in April this year and the recent announcement of an agreement with KSL in the US.

Key Points: 
  • This latest partnership follows the successful launch of PredictSURE IBD in the UK and Ireland in April this year and the recent announcement of an agreement with KSL in the US.
  • The agreement gives patients across Theradiags French speaking territories access to the first prognostic test for IBD, enabling them to get a preview of their future disease outcomes at the point of diagnosis.
  • The agreement enables Theradiag to enhance its offering to clinicians; providing more comprehensive support for IBD patients - from a test predicting future disease severity at diagnosis to the monitoring of treatment throughout the patients journey.
  • We are very pleased and honoured to have been chosen by PredictImmune for these specific missions across these five geographic areas.